The 9th Molecular Virology Meeting (MVM 2026) concluded on September 18 at BRIC–National Institute of Immunology (BRIC–NII), New Delhi, bringing together around 200 clinicians, researchers and students from across India to discuss emerging developments in viral biology and the translation of virology research into vaccines, therapeutics, diagnostics and public-health capabilities.
Initiated in 2009, the Molecular Virology Meeting has evolved into an annual platform for India’s virology community. The 2026 edition was hosted by BRIC–NII with support from the International Centre for Genetic Engineering and Biotechnology (ICGEB) and the Regional Centre for Biotechnology (RCB).
The two-day meeting covered research across a wide range of viral systems, including influenza, dengue, chikungunya, HIV, hepatitis E, West Nile virus, coronaviruses and respiratory syncytial virus. Discussions examined viral entry and replication, host responses, immune regulation, viral evolution and immune evasion, as well as molecular mechanisms underlying viral diseases.
A major focus of MVM 2026 was strengthening the connection between fundamental virology research and its translation into practical solutions. Sessions on translational virology highlighted work involving antiviral therapeutics, antibody discovery, theranostics, viral evolution and epidemiology.
The meeting also examined India’s preparedness and innovation ecosystem in virology. A panel discussion on the future of virology research and its contribution to BioE3 and Viksit Bharat brought together experts from academia, research institutions and industry to discuss technology development, funding for translational research, academia–industry–government partnerships, and capabilities for viral disease surveillance and health security.
The programme featured seven scientific sessions, spotlight talks, poster presentations and a panel discussion, followed by an award ceremony and concluding session.
The meeting highlighted the growing need to connect scientific discoveries with technologies, healthcare solutions and preparedness mechanisms to address emerging and evolving viral health challenges.